|
EQS-Ad-hoc: M1 Kliniken AG / Key word(s): Share Buyback Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 M1 Kliniken AG decides to start share buyback Berlin, 20 April 2023 - The Management Board of M1 Kliniken AG today resolved to repurchase up to 1,500,000 shares of the Company in a maximum total volume of EUR 10,800,000.00 (excluding incidental acquisition costs). The resolution is based on the authorization of the Annual General Meeting of 9 July 2020 to acquire own shares. The buyback program is to start on 28 April 2023 and to be completed by the end of 26 April 2024 at the latest. The share buyback and the purchase settlement will be carried out exclusively by a credit institution or an investment firm, which will decide on the timing of the acquisition of shares independently of and without influence by the Company. The sole purpose of the share buyback program is to use the repurchased shares for all purposes provided for in the authorization resolution of the Company's Annual General Meeting of 9 July 2020 and for all other purposes permitted by the Company's share law.. The buy-back program and its implementation shall take place in compliance with the requirements of the safe harbor regulations pursuant to Art. 5 para. 2 of the Market Abuse Regulation (EU) No. 596/2014 and Art. 2, 3 and 4 of the Delegated Regulation (EU) No. 2016/1052, with the exception of the purpose of the buy-back. This is broader than determined by Art. 5 (2) of the Market Abuse Regulation. About M1 Kliniken AG M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at 55 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 Group has been pushing its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia, Hungary, and Australia. With its stake in HAEMATO AG, M1 Kliniken AG is also able to exploit sales and earnings potential of treatment products in the medical-aesthetic field. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin Telefon: +49 (0)30 347 47 44 14 E-Mail: ir@m1-kliniken.de End of Inside Information
20-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1612961 |
| End of Announcement | EQS News Service |
|
|
1612961 20-Apr-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
